
## Job A J Verdonschot

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/262516/publications.pdf Version: 2024-02-01



LOB A LVERDONSCHOT

#	Article	IF	CITATIONS
1	Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. European Heart Journal, 2018, 39, 864-873.	1.0	132
2	Relevance of cardiac parvovirus <scp>B19</scp> in myocarditis and dilated cardiomyopathy: review of the literature. European Journal of Heart Failure, 2016, 18, 1430-1441.	2.9	108
3	A mutation update for the <i>FLNC</i> gene in myopathies and cardiomyopathies. Human Mutation, 2020, 41, 1091-1111.	1.1	92
4	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart â€~OMics' in AGEing (HOMAGE) randomized clinical trial. European Heart Journal, 2021, 42, 684-696.	1.0	77
5	Prognostic Relevance of Gene-Environment Interactions in Patients WithÂDilated Cardiomyopathy. Journal of the American College of Cardiology, 2015, 66, 1313-1323.	1.2	76
6	Immunosuppressive Therapy Improves Both Short- and Long-Term Prognosis in Patients With Virus-Negative Nonfulminant Inflammatory Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e004228.	1.6	65
7	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. Circulation: Heart Failure, 2019, 12, e005897.	1.6	63
8	Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences. European Heart Journal, 2021, 42, 162-174.	1.0	62
9	Implications of Genetic Testing in Dilated Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, 476-487.	1.6	52
10	Clinical Phenotype and Genotype Associations With Improvement in Left Ventricular Function in Dilated Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e005220.	1.6	51
11	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC: Heart Failure, 2021, 9, 268-277.	1.9	46
12	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proofâ€ofâ€concept, randomised, precisionâ€medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. European Journal of Heart Failure, 2020, 22, 1711-1723.	2.9	43
13	Value of Speckle Tracking–Based Deformation Analysis in Screening Relatives ofÂPatients With Asymptomatic Dilated Cardiomyopathy. JACC: Cardiovascular Imaging, 2020, 13, 549-558.	2.3	40
14	Role of Targeted Therapy in Dilated Cardiomyopathy: The Challenging Road Toward a Personalized Approach. Journal of the American Heart Association, 2019, 8, e012514.	1.6	39
15	The combination of carboxyâ€terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy–ÂA multilevel assessment of myocardial fibrosis in dilated cardiomyopathy. European lournal of Heart Failure. 2021. 23. 933-944.	2.9	34
16	Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus <scp>B19</scp> persistence: a prospective, doubleâ€blind, randomized, placeboâ€controlled clinical trial. European Journal of Heart Failure, 2021, 23, 302-309.	2.9	24
17	Prevalence of Pathogenic Gene Mutations and Prognosis Do Not Differ in Isolated Left Ventricular Dysfunction Compared With Dilated Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e004682.	1.6	22
18	Metabolic Profiling Associates with Disease Severity in Nonischemic Dilated Cardiomyopathy. Journal of Cardiac Failure, 2020, 26, 212-222.	0.7	22

JOB A J VERDONSCHOT

#	Article	IF	CITATIONS
19	Global Longitudinal Strain is Incremental to Left Ventricular Ejection Fraction for the Prediction of Outcome in Optimally Treated Dilated Cardiomyopathy Patients. Journal of the American Heart Association, 2022, 11, e024505.	1.6	21
20	Heart Failure WithÂRecovered Ejection Fraction. Journal of the American College of Cardiology, 2018, 72, 1557-1558.	1.2	20
21	Clinical impact of re-evaluating genes and variants implicated in dilated cardiomyopathy. Genetics in Medicine, 2021, 23, 2186-2193.	1.1	17
22	A global longitudinal strain cutâ€off value to predict adverse outcomes in individuals with a normal ejection fraction. ESC Heart Failure, 2021, 8, 4343-4345.	1.4	17
23	Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. European Journal of Heart Failure, 2020, 22, 1586-1597.	2.9	16
24	Biomarkerâ€based assessment of collagen crossâ€linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the <scp>HOMAGE</scp> clinical trial. European Journal of Heart Failure, 2022, 24, 321-331.	2.9	16
25	Evaluation of the Interaction of Sex Hormones and Cardiovascular Function and Health. Current Heart Failure Reports, 2022, 19, 200-212.	1.3	15
26	Prevalence and clinical outcomes of dystrophinâ€essociated dilated cardiomyopathy without severe skeletal myopathy. European Journal of Heart Failure, 2021, 23, 1276-1286.	2.9	14
27	Mutations in <i>PDLIM5</i> are rare in dilated cardiomyopathy but are emerging as potential disease modifiers. Molecular Genetics & amp; Genomic Medicine, 2020, 8, e1049.	0.6	11
28	Identification of sexâ€specific biomarkers predicting newâ€onset heart failure. ESC Heart Failure, 2021, 8, 3512-3520.	1.4	11
29	Improving diagnosis and risk stratification across the ejection fraction spectrum: the Maastricht Cardiomyopathy registry. ESC Heart Failure, 2022, 9, 1463-1470.	1.4	9
30	Dynamic Ejection Fraction Trajectory in Patients With Dilated Cardiomyopathy With a Truncating Titin Variant. Circulation: Heart Failure, 2022, 15, 101161CIRCHEARTFAILURE121009352.	1.6	9
31	Parvovirus B19 in Dilated Cardiomyopathy: There Is More Than Meets the Eye. Journal of Cardiac Failure, 2019, 25, 64-66.	0.7	8
32	Distinct Cardiac Transcriptomic Clustering in Titin and Lamin A/C-Associated Dilated Cardiomyopathy Patients. Circulation, 2020, 142, 1230-1232.	1.6	7
33	Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. Cardiovascular Diabetology, 2021, 20, 163.	2.7	7
34	Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the <scp>HOMAGE</scp> trial. European Journal of Heart Failure, 2022, 24, 771-778.	2.9	7
35	Cardiac Inflammation Impedes Response to Cardiac Resynchronization Therapy in Patients With Idiopathic Dilated Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008727.	2.1	6
36	The HFAâ€PEFF score identifies â€~earlyâ€HFpEF' phenogroups associated with distinct biomarker profiles. ESC Heart Failure, 2022, 9, 2032-2036.	1.4	6

#	Article	IF	CITATIONS
37	Parvovirus B19 DNA detectable in hearts of patients with dilated cardiomyopathy, but absent or inactive in blood. ESC Heart Failure, 2021, 8, 2723-2730.	1.4	5
38	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	1.4	4
39	Interatrial Block Predicts Lifeâ€Threatening Arrhythmias in Dilated Cardiomyopathy. Journal of the American Heart Association, 2022, 11, .	1.6	4
40	The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. Journal of Cardiac Failure, 2021, , .	0.7	3